Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
MK-677, Oral ghrelin receptor agonist
An orally active non peptide ghrelin receptor agonist that reliably raises GH and IGF-1, studied across GH deficiency, sarcopenia, and aging, with a notable cardiac safety flag.

An oral, non peptide ghrelin receptor agonist that reliably raises GH and IGF-1, though the biomarker rise hasn't translated into the outcomes users want.
Biomarker rise
Muscle & function
Disease progression
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Adunsky A, et al.
IGF-1 rose 84% vs 17% placebo, but the trial was halted early on a congestive heart failure signal (4/62 vs 1/61).
Studied for nearly 30 years across GH deficiency, sarcopenia/frailty, hip fracture recovery, obesity, and Alzheimer's, never approved for any indication. An Alzheimer's RCT showed no clinical benefit. The biomarker (IGF-1) rise does not translate to the functional outcomes users want.
A Phase IIb hip fracture trial was halted early on a congestive heart failure signal (Adunsky et al., 2011): CHF in 4/62 (6.5%) on MK-677 vs 1/61 (1.7%) on placebo. Also causes insulin resistance, raised fasting glucose/HbA1c, increased appetite, fluid retention/edema, and raised blood pressure.
Heart failure history/risk; diabetes/prediabetes; active malignancy; elderly with cardiac vulnerability.
Not FDA approved; investigational. 2024 PCAC recommended against bulks list inclusion. WADA prohibited (S2, ibutamoren named).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.